5-(chloromethyl)-1,2,3,4-tetrahydronaphthalene | 17450-62-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 5-(chloromethyl)-1,2,3,4-tetrahydronaphthalene
• 英文别名: 5-chloromethyl-1,2,3,4-tetrahydronaphthalene；5-chloromethyl-1,2,3,4-tetrahydro-naphthalene；5-Chlormethyl-1,2,3,4-tetrahydro-naphthalin；1-chloromethyl-5,6,7,8-tetrahydronaphthalene；5-Chlormethyl-tetralin；1-Chlormethyl-5,6,7,8-tetrahydronaphthalin
• CAS: 17450-62-3
• 化学式: C₁₁H₁₃Cl
• 分子量: 180.677
• InChiKey: RHDZJMWEZVMVPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5-(chloromethyl)-1,2,3,4-tetrahydronaphthalene 在 palladium on activated charcoal 、 乙醇 作用下， 生成 4-萘-1-基丁烷-2-酮
  参考文献：
  名称：

  The Catalytic Dehydrogenation of 5-Substituted 1,2,3,4-Tetrahydronaphthalene Derivatives

  摘要：

  DOI：

  10.1021/ja01124a013
• 作为产物：
  描述：

  茚满-4-甲酸甲酯 在 吡啶 、 lithium aluminium tetrahydride 、 氯化亚砜 、 乙醚 、 甲苯 作用下， 生成 5-(chloromethyl)-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  The Catalytic Dehydrogenation of 5-Substituted 1,2,3,4-Tetrahydronaphthalene Derivatives

  摘要：

  DOI：

  10.1021/ja01124a013

文献信息

• [EN] ANTIBACTERIAL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ANTIBACTÉRIENS ET UTILISATIONS DE CEUX-CI
  申请人：THE GLOBAL ALLIANCE FOR TB DRUG DEV INC

  公开号：WO2017155909A1

  公开（公告）日：2017-09-14

  The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

  本发明涉及式(I)的化合物，包括其任何立体化异构体或其药学上可接受的盐，用于治疗结核病。
• Compositions and methods for producing a vasodilatory effect with a
  申请人：Lipha, Lyonnaise Industrielle Pharmaceutique

  公开号：US03973033A1

  公开（公告）日：1976-08-03

  The present invention relates to substituted tetrahydrofurfuryl aminoesters. The novel tetrahydrofurfuryl dialkyl aminoesters are represented by the formula ##EQU1## in which R is a member of the group formed by the 2-naphthyl, 2-naphthyl substituted in the 6-position with alkoxy and 5,6,7,8-tetrahydro-1-naphthyl radicals. The addition salts with the therapeutically acceptable acids, the starting and intermediate products of these aminoesters, also form the subject of the invention. The novel aminoesters and their salts, endowed with peripheral and cerebral vasodilatory properties, are of particular interest in human therapeutics.

  本发明涉及取代的四氢呋喃基氨基酯。新型四氢呋喃基二烷基氨基酯由以下公式表示：##EQU1## 其中R是由2-萘基、在6-位上用烷氧基取代的2-萘基和5,6,7,8-四氢-1-萘基基团形成的群体中的一员。这些氨基酯的治疗上可接受的酸盐、起始和中间产物也是本发明的主题。这些具有周围和脑血管扩张性能的新型氨基酯及其盐，在人类治疗方面具有特别的兴趣。
• Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0003560A2

  公开（公告）日：1979-08-22

  Pharmaceutical formulations comprising an imidazole (or pharmaceutically acceptable salt thereof) of formula: wherein (i) A is an aliphatic hydrocarbon residue of from 1 to 4 carbon atoms and R is a naphthyl, tetrahydronaphthyl, heterocyclyl, arylthio, arylalkylthio, aryloxy, arylalkyloxy, arylhydroxymethylene, arylcarbonyl, arylalkylcarbonyl, alkyloxy, alkylthio or a substituted cycloalkyl or cycloalkenyl group or (ii) A is a -S02- group and R is aryl or heterocyclyl or (iii) A is a chemical bond and R is a heterocyclyl or substituted phenyl group, or (iv) A is an aliphatic hydrocarbon residue of from 1 to 3 carbon atoms and R is a halophenyl group. Some of these imidazoles and salts are novel. Methods of preparing the imidazoles are disclosed. The imidazoles and their salts are useful in the treatment or prophylaxis of thrombo-embolic conditions.

  药物制剂，包含式中的咪唑（或其药学上可接受的盐）： 其中 (i) A 是 1 至 4 个碳原子的脂族烃残基，R 是萘基、四氢萘基、杂环基、芳硫基、芳烷硫基、芳氧基、芳烷氧基、芳羟甲基、芳羰基、芳烷基羰基、烷氧基、烷硫基或取代的环烷基或环烯基，或 (ii) A 是-S02-基团，R 是芳基或杂环基，或 (iii) A 是化学键，R 是杂环基或取代苯基，或 (iv) A 是 1 至 3 个碳原子的脂肪烃残基，R 是卤代苯基。 其中一些咪唑和盐是新型的。 这些咪唑的制备方法已经公开。咪唑及其盐类可用于治疗或预防血栓栓塞。
• Antibacterial compounds and uses thereof
  申请人：The Global Alliance for TB Drug Development, Inc.

  公开号：US10508097B2

  公开（公告）日：2019-12-17

  The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

  本发明涉及用于治疗结核病的式 (I) 化合物，包括其任何立体化学异构体形式，或其药学上可接受的盐类。
• 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel
  作者：Hamish S. Sutherland、Amy S.T. Tong、Peter J. Choi、Adrian Blaser、Daniel Conole、Scott G. Franzblau、Manisha U. Lotlikar、Christopher B. Cooper、Anna M. Upton、William A. Denny、Brian D. Palmer

  DOI：10.1016/j.bmc.2019.02.026

  日期：2019.4

  Bedaquiline is a new drug of the diarylquinoline class that has proven to be clinically effective against drugresistant tuberculosis, but has a cardiac liability (prolongation of the QT interval) due to its potent inhibition of the cardiac potassium channel protein hERG. Bedaquiline is highly lipophilic and has an extremely long terminal half-life, so has the potential for more-than-desired accumulation in tissues during the relatively long treatment durations required to cure TB. The present work is part of a program that seeks to identify a diarylquinoline that is as potent as bedaquiline against Mycobacterium tuberculosis, with lower lipophilicity, higher clearance, and lower risk for QT prolongation. Previous work led to the identification of compounds with greatly-reduced lipophilicity compounds that retain good anti-tubercular activity in vitro and in mouse models of TB, but has not addressed the hERG blockade. We now present compounds where the C-unit naphthalene is replaced by a 3,5dialkoxy- 4-pyridyl, demonstrate more potent in vitro and in vivo anti-tubercular activity, with greatly attenuated hERG blockade. Two examples of this series are in preclinical development.